middle.news
Why Did Invex Therapeutics Abandon a $1.4B Neurological Deal?
10:12am on Tuesday 30th of September, 2025 AEST
•
Healthcare
Read Story
Why Did Invex Therapeutics Abandon a $1.4B Neurological Deal?
10:12am on Tuesday 30th of September, 2025 AEST
Key Points
Exclusive acquisition talks ended due to shareholder-driven board removal notice
Target company focused on Fragile X Syndrome and rare neurodevelopmental disorders
Board intends to continue strategy of portfolio diversification despite challenges
General meeting scheduled for 10 November 2025 to address director removal resolutions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE